The last post here on 23andme

Trusting a private for-profit company with your genetic data was never a good idea.

23andMe is not doing well. Its stock is on the verge of being delisted. It shut down its in-house drug-development unit last month, only the latest in several rounds of layoffs. Last week, the entire board of directors quit, save for Anne Wojcicki, a co-founder and the company's CEO. Amid this downward spiral, Wojcicki has said she'll consider selling 23andMe-which means the DNA of 23andMe's 15 million customers would be up for sale, too